Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer
- PMID: 23182993
- PMCID: PMC3577950
- DOI: 10.1200/JCO.2012.43.6097
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer
Abstract
Purpose: To report the long-term results of the Intergroup Radiation Therapy Oncology Group 91-11 study evaluating the contribution of chemotherapy added to radiation therapy (RT) for larynx preservation.
Patients and methods: Patients with stage III or IV glottic or supraglottic squamous cell cancer were randomly assigned to induction cisplatin/fluorouracil (PF) followed by RT (control arm), concomitant cisplatin/RT, or RT alone. The composite end point of laryngectomy-free survival (LFS) was the primary end point.
Results: Five hundred twenty patients were analyzed. Median follow-up for surviving patients is 10.8 years. Both chemotherapy regimens significantly improved LFS compared with RT alone (induction chemotherapy v RT alone: hazard ratio [HR], 0.75; 95% CI, 0.59 to 0.95; P = .02; concomitant chemotherapy v RT alone: HR, 0.78; 95% CI, 0.78 to 0.98; P = .03). Overall survival did not differ significantly, although there was a possibility of worse outcome with concomitant relative to induction chemotherapy (HR, 1.25; 95% CI, 0.98 to 1.61; P = .08). Concomitant cisplatin/RT significantly improved the larynx preservation rate over induction PF followed by RT (HR, 0.58; 95% CI, 0.37 to 0.89; P = .0050) and over RT alone (P < .001), whereas induction PF followed by RT was not better than treatment with RT alone (HR, 1.26; 95% CI, 0.88 to 1.82; P = .35). No difference in late effects was detected, but deaths not attributed to larynx cancer or treatment were higher with concomitant chemotherapy (30.8% v 20.8% with induction chemotherapy and 16.9% with RT alone).
Conclusion: These 10-year results show that induction PF followed by RT and concomitant cisplatin/RT show similar efficacy for the composite end point of LFS. Locoregional control and larynx preservation were significantly improved with concomitant cisplatin/RT compared with the induction arm or RT alone. New strategies that improve organ preservation and function with less morbidity are needed.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
Comment in
-
Competing roads to larynx preservation.J Clin Oncol. 2013 Mar 1;31(7):833-5. doi: 10.1200/JCO.2012.45.8976. Epub 2013 Jan 22. J Clin Oncol. 2013. PMID: 23341522 No abstract available.
-
Larynx preservation: a debate worth preserving.J Clin Oncol. 2013 Sep 1;31(25):3170. doi: 10.1200/JCO.2013.49.1332. Epub 2013 Jul 29. J Clin Oncol. 2013. PMID: 23897959 No abstract available.
Similar articles
-
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.J Natl Cancer Inst. 2015 Dec 16;108(4):djv368. doi: 10.1093/jnci/djv368. Print 2016 Apr. J Natl Cancer Inst. 2015. PMID: 26681800 Clinical Trial.
-
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.Ann Oncol. 2009 May;20(5):921-7. doi: 10.1093/annonc/mdn752. Epub 2009 Jan 29. Ann Oncol. 2009. PMID: 19179556 Clinical Trial.
-
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.J Natl Cancer Inst. 2009 Feb 4;101(3):142-52. doi: 10.1093/jnci/djn460. Epub 2009 Jan 27. J Natl Cancer Inst. 2009. PMID: 19176454 Free PMC article. Clinical Trial.
-
A systematic review of current and emerging approaches in the field of larynx preservation.Radiother Oncol. 2014 Jan;110(1):16-24. doi: 10.1016/j.radonc.2013.08.016. Epub 2013 Oct 15. Radiother Oncol. 2014. PMID: 24139733 Review.
-
From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer.Oral Oncol. 2018 Nov;86:200-205. doi: 10.1016/j.oraloncology.2018.09.026. Epub 2018 Oct 1. Oral Oncol. 2018. PMID: 30409302 Review.
Cited by
-
Could Primary Chemoradiotherapy in T2 Glottic Cancers Yield Results Comparable to Primary Radiotherapy in T1? Considerations from 531 German Early Stage Patients.Cancers (Basel). 2021 Mar 31;13(7):1601. doi: 10.3390/cancers13071601. Cancers (Basel). 2021. PMID: 33807125 Free PMC article.
-
Recurrence prediction with local binary pattern-based dosiomics in patients with head and neck squamous cell carcinoma.Phys Eng Sci Med. 2023 Mar;46(1):99-107. doi: 10.1007/s13246-022-01201-8. Epub 2022 Dec 5. Phys Eng Sci Med. 2023. PMID: 36469245
-
Non-surgical organ preservation strategies for locally advanced laryngeal tumors: what is the Italian attitude? Results of a national survey on behalf of AIRO and AIOM.Med Oncol. 2016 Jul;33(7):76. doi: 10.1007/s12032-016-0781-5. Epub 2016 Jun 11. Med Oncol. 2016. PMID: 27290695
-
Definitive chemo-radiotherapy in cervical oesophageal cancer: a comprehensive review of literature.Rep Pract Oncol Radiother. 2024 Jul 22;29(3):391-408. doi: 10.5603/rpor.100777. eCollection 2024. Rep Pract Oncol Radiother. 2024. PMID: 39144270 Free PMC article. Review.
-
[Laryngectomy-still state of the art?].HNO. 2019 Dec;67(12):955-976. doi: 10.1007/s00106-019-00769-0. HNO. 2019. PMID: 31720696 German.
References
-
- Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–2098. - PubMed
-
- Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324:1685–1690. - PubMed
-
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
-
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170. - PubMed
-
- Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources